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Isoniazid and hydralazine were covalently crosslinked 
by epidermal transglutaminase to serum and cell nuclear 
proteins. Albumin and nUcleohistones were excellent 
acceptors of these drugs in serum and nuclear extracts, 
respectively. Drug-albumin and drug-histone conjugates 
were highly antigenic in rabbits within 4 weeks, eliciting 
drug-specific antibodies in all immunized animals. A 
radioimmunoassay for antibodies to isoniazid was de-
veloped, using a standard drug-albumin conjugate. 
The methods described here of enzymatic crosslinking 
of drugs to proteins facilitate studies of drug-induced 
hypersensitivity in animals and man. 
Immune reactions to drugs are frequently associated with the 
development of circulating drug-specific antibodies; current 
methods of quantitating these antibodies, although sensitive, 
are cumbersome and difficult to standardize. 
Lorand, Campbell, and Robertson observed in 1972 [1] that 
2 drugs capable of inducing drug-specific antibodies in man, 
isoniazid (INH) and hydralazine (HYD) were excellent sub-
strates for plasma transglutaminase. This enzyme ordinarily 
mediates covalent crosslinking between glutamine and lysine 
residues of fibrin, but can easily substitute small primary 
amines, such as INH or HYD for the lysine moiety of the 
reaction. Lorand, Campbell, and Robertson showed that both 
~brin and serum albumin could be covalently labeled with drug 
m the presence of transglutaminase. Such accidental crosslink-
ing, if it occurred in uiuo, could create highly antigenic com-
pounds capable of causing immune or autoimmune reactions, 
such as have been described following administration of INH 
[2-4). 
In order to study further the enzymatic crosslinking of INH 
and HYD to tissue proteins and the immunologic consequences 
of such crosslin king, the findings of Lorand, Campbell, and 
Robertson with plasma transglutaminase and serum proteins 
were extended to include an intracellular enzyme, epidermal 
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Abbreviations: 
AIU: Amine-Incorporating Units 
EN A: Extractable Nuclear Antigens 
HSA: Human Serum Albumin 
HYD: Hydralazine 
1NH: Isoniazid 
RNP: Ribonucleoprotein 
RSA: Rabbit Serum Albumin 
TBS: 0.05 M Tris-0.15 M NaCI, pH 7.5 
• 120 min was chosen as endpoint because epidermal transglutamin-
ase approaches 50% initial activity at this time. 
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transglutaminase, capable of covalently crosslinking drug and 
nuclear constituents. Serum albumin and cell nuclear proteins 
were investigated as acceptors for INH and HYD. Drug-protein 
conjugates of known molar ratio were used to induce drug-
specific antibodies in rabbits, and a radioimmunoassay using 
standardized 3H-INH-alburnin conjugates was developed. 
MATERIALS AND METHODS 
' H-isoniazid ("H-INH) with a specific activity of 5.1 mCi/mg was 
purchased from Amersham (Arlington Heights, ILl . A 10 mM solution 
of cold INH was mixed with "H-INH to a specific activity of 1.25 x 10- ' 
mCi/mM. Hydralazine hydrochloride, rabbit and human serum albu-
min, lysine-rich histones, purified native calf thymus DNA, RNAase-
free sucrose and enzyme grade Trizma base were obtained from Sigma 
(St. Louis, MOl , and precast Ouchterlony plates from Hyland Labora-
tories (Oakland, CAl. 
Extractable nuclear antigen (EN A) and deoxyribonucleoprotein were 
prepared from fresh calf thymus according to the methods of AUfrey, 
Littau, and Mirsky [5] and Tan [6]. Immediately prior to use they were 
dialyzed into TBS and the protein concentration adjusted to 2 mg/ml. 
The presence of immunologicaUy intact Sm and RNP antigens within 
the ENA preparation were verified by Ouchterlony diffusion against 
known positive sera. 
Epidermal transglutaminase, purified from bovine epidermis as pre-
viously described [7], had an activity of 86.1 amine-incorporating unitsl 
ml. Protein concentrations were determined [8), using bovine albumin 
as standard. 
Serum and nuclear proteins (histones, DNA, ENA, deoxyribonucleo-
protein) were evaluated for their relative ability to incorporate JH-INH 
in the presence of transglutaminase. A timed 60 min incorporation 
study was carried out; duplicate assays were performed, using the same 
batch of enzyme, in an assay medium containing 1 mg nuclear protein, 
10 roM Ca' + and 0.1 rnl purified transglutaminase in a total volume of 
0.85 rnl at 37°C, pH 7.5. Calcium chloride was added to initiate enzy-
matic coupling and the reaction was stopped from 0-60 min with excess 
EDTA. FoUowing exhaustive dialysis against TBS to remove unbound 
lNH, 50/-,I aliquots of the reaction mixture were counted in duplicate 
in a Beckman Liquid Scintillation Counter. Specific ac.tivity of the 
conjugates was calculated by proportionality against the starting solu-
tion of lNH. 
For gel filtration, Sephadex G200 was obtained from Pharmacia 
(Uppsala, Sweden) and was performed under standard conditions at 
pH 7.5, 25°C with TBS as eluting buffer. The column was precalibrated 
with Blue Dextran, y-globulin, RSA and Cytochrome C (Sigma) . 
Hydralazine and isoniazid were conjugated with transglutaminase 
for 120 min to HSA, RSA and lysine-rich histones for injection into 
experimental animals. The crosslinlUng medium contained drug at 10 
mM (rma! concentration); transg1utaminase, 0.25 ml (specific activity 
11.4 AIU I ml); carrier protein, 4 mglrnl (avg mw histones = 20,(00) . 
Unreacted drug was removed by dialysis against TBS - 1 mM EDTA 
and extent of drug conjugation measured. Unreacted drug was removed 
by dialysis against TBS - 1 roM EDT A, and extent of INH conjugation 
measured as above for isoniazid. Conjugation of hydralazine to protein 
was quantitated by measuring the change in absorbance at 275 nm and 
comparing this with a standard solution of hydralazine in TBS [9]. The 
contribution due to protein absorption was measured separately and 
subtracted. Pairs of New Zealand whit.e rabbits received initial foot pad 
injections with 1.5 mg conjugate in complete Freund's adjuvant. They 
were given booster injections of 0.75 mg emulsified in incomplete 
adjuvant every 2 weeks thereafter until sacrifice. Control animals were 
inoculated with either drug or carrier protein alone in amounts equal 
to conjugated amounts. Blood was drawn on alternate weeks for deter-
mination of antidrug antibodies. Injections were continued until anti-
body titers dropped, which occurred at approximately 6 mo after initial 
injection. Antibodies directed against the immunogens were identified 
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by Ouchterlony diffusion of experimental sera against the drug alone 
(using isoniazid crosslinked to casein), the immunizing drug-carrier 
complex, and the carrier protein alone. 
Drug-specific antibodies to INH were quantitated in a radioimmu-
noassay conducted by modified Minden and Farr technique [10). Ali-
quots of 0.1 ml of doubling dilutions of experimental serum were 
incubated overnight at 4°C with constant amounts (0.23 nM of specific 
activity 1.25 x 10 • mC/ mM) 3H-INH bound to serum albumin (in a 0.1 
m1 volume) . Following incubation, a 0.2 ml volume of saturated am-
monium sulfate was added. Precipitates were centrifuged at 4· C and 
3000 xg for 20 min, washed with cold 50% saturated ammonium sulfate, 
recentrifuged, and the radioactivity in the precipitate was counted in a 
well-type scintillation counter. Results were expressed as the ABC3!) of 
the experimental serum. The ABC", value represents the amount of 
3H -INH bound per ml undiluted serum at the antigen concentration 
employed (in this case, 0.23 nM of specific activity 1.25 X 10- ' mC/ mM 
antigen) . The ABC,,'l endpoint is the reciprocal of the serum dilution 
which precipitates 33% of the labeled antigen added. 
RESULTS 
Isoniazid was enzymatically crosslinked in linear fashion with 
time to rabbit serum proteins. Analysis of labeled serum by gel 
filtration chromatography showed that 60-80% of the recovered 
radioactivity eluted with a protein peak of 67,000 daltons in 
molecular weight which contained immunoreactive rabbit se-
rum albumin by Ouchterlony diffusion. The remainder was 
distributed rather evenly among 3 other protein peaks which 
were not further identified. Purified RSA and HSA incorpo-
rated :lH-INH similarly, 0.15 mole INH per mole albumin under 
identical experimental conditions, in 120 min of incubation 
time. 
Histones coupled most rapidly to INH among the various 
nuclear constituents examined (Fig I), and since they could be 
obtained in relatively purified form, were selected as a repre-
sentative nuclear antigen for conjugation to INH and animal 
immunjzation. ENA incorporated lesser amounts of radioactiv-
ity and demonstrated a prolonged lag phase in accepting the 
drug. DNA and deoxyribonucleoprotein djd not incorporate the 
drug. Specific activity of histone-INH conjugate was 0.02 mole 
INH per mole histone. 
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FIG 1. Incorporation of 3H-INH into calf thymus nuclear proteins 
with time. H = histones; ENA = extractable nuclear antigens; Snp -
deoxyrihonucleoprotein; DNA - native DNA. 
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FIG 2. Ouchterlony plate showing INH-specific antibodies raised in 
rabbits in1munized with INH crosslinked enzymatically to different 
proteins. Center well contains INH-casein; Wells 1-4 contain, respec-
tively, antisera directed against the following immunogens: INH-RSA, 
INH-HSA, INH alone, INH-histones. 
FIG 3. Ouchterlony plate demonstrating antibodies against both 
INH and heterologous carrier protein in rabbit immunized with INH-
HSA. Center well: antiserum from immunized animal, diluted 1:1. Well 
1: INH-casein. Wells 2, 3: human serum albumin. 
In all animals receiving isoniazid crosslinked to a protein 
carrier, precipitating antibodies to the drug were detectable by 
the 4th week following primary immunization, independent of 
the carrier. At that time no animal had received more than the 
equivalent of 1 Ilg of drug antigen. The line of identity seen in 
the Ouchterlony plate in Fig 2, depicting sera from animals 
receiving different carriers diffused against INH-casein conju-
gate indicates that the INH determinant was antigenic in all 
animals. 'This precipitin line disappeared from Ouchterlony 
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FIG 4. Antigen-binding capacity (ABC-33) of sera from rabbits im-
munized with INH crosslinked by transglutaminase to different carriers. 
Symbols: 0---0, INH-histones; A- A , INH-HSA; ....__., INH-
RSA; +.-.-+, INH alone (see text for experimental deta~ 
plates containing antisera previously absorbed with free isoni-
azid. Rabbits receiving only drug in adjuvant did not fonn 
antidrug antibodies; antibodies to carrier protein were observed 
only in animals injected with heterologous serum albumin (Fig 
3). 
Fig 4 demonstrates relative rises in drug antibody titer by 
radioimmunoassay. Antibody titers increased rapidly in all an-
imals independent of protein carrier, and did not seem to be 
significantly elevated by the presence of the foreign HSA car-
rier. Again no antibodies were found in animals receiving un-
bound isoniazid. The minimum sensitivity of the radioimmu-
noassay was calculated at 5 ng bound conjugate. 
Preliminary experience using hydralazine as primary amine 
substrate have yielded similar results. Hydralazine couples to 
RSA approximately 10 X more efficiently than INH under 
identical experimental conditions, suggesting that this drug may 
be a better substrate for transglutaminase. Drug-specific pre-
cipitin antibodies to hydralazine develop within 4 weeks of 
primary immunization. 
DISCUSSION 
The demonstration in this study that conjugation of a drug 
to a variety of cell nuclear proteins can be carried out with an 
intracellular transglutaminase offers a significant improvement 
over previous models for studying drug-induced hypersensitiv-
ity. Enzymatic coupling is gentle, and can be easily controlled 
by altering conditions of the reaction such as temperature, pH, 
enzyme concentration, or time. Selecting different carrier pro-
teins, or increasing the rate and extent of drug crosslinking 
experimentally may produce conjugates capable of breaking 
tolerance to self-antigens. 
It is tempting to speculate upon the relevance of this animal 
model to study of the pathogenesis of immune (e.g. vasculitis) 
and autoimmune (e.g. lupus-like) reactions to INH and HYD, 
as well as to other drugs such as procainamide. The incidence 
of drug-induced reactions to INH and HYD is time and dose-
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dependent [11,12]. Recent data suggest that a free amine group 
on the drug is essential for induction of drug hypersensitivity, 
since persons who are slow acetylators of the amine group of 
INH, HYD and procainamide have an increased incidence of 
immune reactions, and administration ofN-acetyl procainamide 
prevents these reactions while retaining the drug's anti-ar-
rhythmic properties [13]. Correlation of the presence of drug-
specific antibody with symptomatic drug hypersensitivity is 
well documented, at least with respect to hydralazine [14]. INH 
induces a much lower incidence of hypersensitivity. One study 
(Yamauchi et al [15]) defmed a defmite relationship between 
antihydralazine antibodies and antinuclear activity using highly 
conjugated hydralazine-HSA conjugates. Antibodies to histone 
have recently been implicated in INH-induced hypersensitivity 
reactions (16). 
Thus, the finding that transglutaminase-catalyzed drug-pro-
tein conjugates are highly immunogenic, and that such reac-
tions are capable of occurring in vivo as well as in vitro, offers 
opportunity for more extensive investigations of controlled drug 
induced hypersensitivity in experimental animals and humans. 
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